FDA approves GSK drug for endometrial cancer with specific genetic signature April 22, 2021 Auto Bot BioPharma, biopharma nl, cancer, Clinical Trials, endometrial cancer, FDA, GlaxoSmithKline, Pharma 0 The FDA approved GlaxoSmithKlie drug dostarlimab (Jemperli) for endometrial cancer that carries a particular genetic signature. The immunotherapy now joins Merck’s Keytruda as the checkpoint inhibitors approved for treating endometrial cancer.